NEW YORK (360Dx) – British diagnostics firm Mologic today said that it has received CE marking for its Periplex point-of-care test for detection of infections in patients undergoing peritoneal dialysis.
The company said that it also has launched the test.
The Periplex test detects two biomarkers of infection – Interleukin 6 and Matrix Metalloproteinase-8 –in peritoneal dialysis waste fluid using a lateral flow immunoassay system and provides results within 10 minutes compared to more than 24 hours for other current methods, the firm said. Earlier detection of an infection could enable patients to contact their healthcare provider more quickly to initiate antibiotic therapy.
Mark Davis, co-founder and CEO of Bedfordshire, UK-based Mologic, noted in a statement that the firm also has Periplex tests in development for sepsis, urinary tract infections, and chronic obstructive pulmonary disease.